Overview
Celemics’ G-Mendeliome Clinical Exome Sequencing (CES) Panel is
designed to overcome the limitations of analyzing clinical diseases
with conventional whole-exome sequencing.
genetic variations within target genes in the human genome. The G-Mendeliome CES Panel includes both clinically significant genes used in other panels
and other additional genes, therefore allowing customers to obtain comprehensive
information of mutations in genes of interest in a cost-effective manner.
Features &
Benefits
-
- Comprehensive genomic profiling of a variety of genetic diseases
- Includes 7,000 genes associated with clinically significant genetic diseases
-
- A wide range of target regions
- Includes all clinically significant regions that are not covered by competitor's panels
-
- Cost-effective analysis
- Able to provide accurate analysis with reduced sequencing
costs compared to WES
Performance
Design of G-Mendeliome CES panel and comparison data
G-Mendeliome CES
Company A + Company B + over 70 genes
The CES Panel was developed to meet the needs of GC Genome,
the largest clinical NGS service provider in South Korea,
to solve the problems of poor diagnostic rates and high costs.
Comparison data: ZNF419 gene
Comparison data: COL6A5 gene
Through the in-house manufacturing and probe design system of Celemics, customers can request the sequencing of homolog regions as well as hare-to capture regions
The comparison data showed obtained sequencing reads for ZNF419 and COL6A5 genes, which are commonly masked in other panels.
G-Mendeliome CES Target Diseases
G-Mendeliome CES panel contains around 7,000 disease-related genes as target regions. The related diseases are listed in the table below.
Applications
-
Research for germline cancer
-
Research for Inherited disease